Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 61 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cholecalciferol - CKD Clear all

Conditions: Vitamin D Metabolism is in Chronic Kidney Disease
Interventions: 10,000 IU of cholecalciferol for a total of 8 weeks; Drug
Lead sponsor: Memphis VA Medical Center; Federal
Eligibility: 18 Years to 85 Years · Male only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Diabetes Mellitus, Chronic Kidney Disease, Diabetic Kidney Disease
Interventions: Cholecalciferol, Placebo; Dietary Supplement
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Arterial Dysfunction, Chronic Kidney Disease
Interventions: Cholecalciferol, Calcitriol; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Chronic Kidney Disease, Vitamin D Deficiency
Interventions: Ergocalciferol, Calcitriol; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Chronic Kidney Disease
Interventions: Paricalcitol; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Anemia of Chronic Kidney Disease
Interventions: Cholecalciferol; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 1 Year to 21 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Kidney Disease
Interventions: D6-25-hydroxyvitamin D3; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chronic Kidney Disease
Interventions: Vitamin D2 (ergocalciferol), Vitamin D3 (cholecalciferol); Dietary Supplement
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Renal Osteodystrophy
Interventions: doxercalciferol, Cholecalciferol; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 82 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Chronic Kidney Disease
Interventions: 1000 IU of Vitamin D3, 4000 IU of Vitamin D3; Drug
Lead sponsor: Emory University; Other
Eligibility: 9 Years to 21 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions: Paricalcitol, Calcitriol; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 4
States / cities: Chicago, Illinois • Evanston, Illinois • Detroit, Michigan + 1 more

Conditions: Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency, CKD Stage 3, CKD Stage 4
Interventions: Calcifediol Oral Capsule, Calcifediol Oral Product, Cholecalciferol, Paricalcitol Oral Capsule; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Garden Grove, California • Chicago, Illinois • West Bend, Wisconsin

Conditions: Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Vitamin d Deficiency, Secondary Hyperparathyroidism
Interventions: CTAP101, Placebo; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Columbus, Ohio • Greenville, South Carolina

Conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions: Cinacalcet HCl, Standard of Care; Drug · Dietary Supplement
Lead sponsor: Amgen; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 26
States / cities: Los Angeles, California • Wilmington, Delaware • Atlanta, Georgia + 22 more

Conditions: CKD Stage 3/4
Interventions: Vitamin D 2mg daily for 2 weeks oral paricalcitol, Placebo; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism, Vitamin D Insufficiency
Interventions: Cohort 1 CTAP101 Capsules- 60µg, Cohort 1 CTAP101 Capsules - 90µg, Cohort 1 Matching Sugar Capsule, Cohort 2 CTAP101 Capsules - 30µg, Cohort 2 Matching Sugar Capsule; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bannockburn, Illinois

Conditions: Coronary Artery Disease, Chronic Kidney Disease, Hypovitaminosis D, Secondary Hyperparathyroidism
Interventions: paricalcitol, placebo; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism, VDI
Interventions: CTAP101; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Kansas City, Missouri • Columbus, Ohio • Philadelphia, Pennsylvania + 2 more

Conditions: Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions: Cinacalcet, active vitamin D analogue; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Lynchburg, Virginia

Conditions: Chronic Kidney Disease, End Stage Kidney Disease, Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy, Secondary Hyperparathyroidism
Interventions: Kidney disease; Other
Lead sponsor: Columbia University; Other
Eligibility: 40 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Secondary Hyperparathyroidism, End-Stage Renal Disease
Interventions: Paricalcitol, Calcitriol; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: Up to 16 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 18
States / cities: Birmingham, Alabama • Gainesville, Florida • Orlando, Florida + 15 more

Conditions: Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary
Interventions: Paricalcitol, Corticosteroid Avoidance Immune Suppression Protocol; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Chronic Kidney Disease (CKD), End-stage Renal Disease (ESRD)
Interventions: Cholecalciferol - CKD, Calcitriol - CKD, Cholecalciferol - non-CKD; Drug · Device
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 21 Years to 90 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
Interventions: CTAP101 Capsules, CTAP101 Injection; Drug
Lead sponsor: OPKO IP Holdings II, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 12
States / cities: Peoria, Arizona • Evergreen Park, Illinois • Springfield, Massachusetts + 9 more

Search by objective public record fields.

Vitamin D Metabolism in Chronic Kidney Disease Patients

Randomized Controlled Trial of Vitamin D3 in Diabetic Kidney Disease

Vitamin D and Arterial Function in Patients With Chronic Kidney Disease

hCAP18 Levels and Vitamin D Deficiency in Chronic Kidney Disease

The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate

Vitamin D as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease

Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease

Differential Effects of Ergocalciferol and Cholecalciferol Therapies in Chronic Kidney Disease

Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease

Two Vitamin D Dosing Strategies in Children With Chronic Kidney Disease

Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)

Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency

Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism

Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis

Identification of Markers for Determining the Efficacy of Vitamin D Receptor Activator Therapy in Stage 3/4 CKD Patients

Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)

Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants

Trial to Optimize Mineral Outcomes in Dialysis Patients

Pathogenesis of Compromised Bone Quality and Mechanics in Chronic Kidney Disease

Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice

Oral Paricalcitol in Kidney Transplant Recipients

Impact of Vitamin D Therapies on Chronic Kidney Disease

Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects